GTNF 2023: Growing Competition in Harm Reduction Products

Industry Insight by 2FIRSTS.ai
Sep.21.2023
GTNF 2023: Growing Competition in Harm Reduction Products
On the morning of September 21st, during the third day of the GTNF Forum, guests discussed the research of harm reduction products, predicting intensified competition in the future.

On the morning of September 21, during the third day of the GTNF Forum, participants engaged in discussions surrounding "Reducing Harm to the Economy: Theory and Practice." By presenting data, they demonstrated the current global status of harm reduction products. The conclusion drawn was that in the future, competition among various types of harm reduction products will intensify.

GTNF探讨减害经济:各类型减害产品竞争将加剧
On-site | 2firsts

 

The forum was hosted by Sinclair Davidson, a renowned writer and economist. The distinguished panel of speakers included Paul Blair, the Regional Director of External Affairs at PMI International; Anna Choi, an Assistant Professor in the Department of Public Administration at Sejong University; James Lambert, the Director of Asian Economic Consultancy at the Oxford Economics Research Institute; David Levy, a professor of oncology at Georgetown University; and Tim Phillips, the Managing Director of Tamarind Intelligence.

 

The guests showcased the distribution of new tobacco products worldwide through data. The usage rate of reduced-risk products has been steadily increasing, with a compound annual growth rate of 69% for nicotine pouches and 32% for heat-not-burn products in the North American market from 2019 to 2023. The market size for e-cigarettes in the region has grown at a compound annual growth rate of 11%. In Europe, the Middle East, and Africa, the compound annual growth rate for nicotine pouches is 41%, while it is 21% for heat-not-burn products and 7% for e-cigarettes. In the Asia-Pacific region, the compound annual growth rate for heat-not-burn products market size is 7%.

 

According to data, the top eight countries in terms of sales for heated tobacco and e-cigarettes in 2022 are the United States, Canada, Russia, the United Kingdom, Germany, Italy, Japan, and South Korea.

 

The attending guests expressed that the current positioning of e-cigarette companies in the United States is unclear due to the FDA's PMTA approval process. The only e-cigarette company without a tobacco background that has obtained PMTA approval is NJOY, which recently was acquired by Altria. Currently, it seems that no other independent e-cigarette company without a tobacco background has been able to pass PMTA. In the HNB field, PMI appears to be prepared to enter the US market, while Altria and JTI are collaborating to enter the US market, indicating the presence of competition in this sector. A similar situation has arisen in the nicotine pouch market, as ZYN and On are competing against each other.

 

Furthermore, in South Korea, the smoking rate among men is as high as 35%. Currently, 85% of those using ENDS are smokers, 12% used to be smokers, and 3% have never smoked before. However, the government's attitude towards harm reduction alternatives is extremely negative. They frequently promote the idea that harm reduction cannot help with smoking cessation, which also influences consumers' choices. This highlights the significant impact the government's attitude towards harm reduction products has on the future of these products.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Related Topics